• Veteran Risk Management Advisor specializing in FX, interest rates, and equity derivatives as well as acquisition strategy and valuation for clients across private equity, financial services, family offices, and mid-cap corporations. • Develop tailored strategies to mitigate risk/de-risk cross border asset-liability mismatches as well as strategically place and invest in opportunities ensuring a balanced approach to risk management and returns.• Advisory services for startup entities in cross-border risk management, best execution and policy formulation. Provide guidance on navigating volatile and illiquid markets, as well as engaging in macro market trading strategies.

· Producing manager with individual corporate, PE, family office/wealth & institutional coverage of FX & structured products.· Led the formation of a dynamic cross-asset distribution team to address the bespoke liability and asset management needs across family office/UHNW WM clients, corporations, financials treasuries, select institutional clients and Latam clients covering FX, rates, equities, structured products & loans.· Served as key UBS interface in evaluating issues affecting corporate risk management policy, international acquisitions, foreign business contracts, portfolio optimization theory and the efficient management of international investment portfolios.· Managed personal relationships with an extensive client portfolio throughout the U.S., Canada and LatAm with a concentration towards Financial Institutions/Fintech, Private Equity, Technology, Pharma & Industrial corporates.· Developed the IB’s derivatives OTC offering focusing on FX/IR alpha, hedging and strategic/hybrid assignments. to UBS Wealth Management Americas following the DF regulatory reform.· Actively managed a portfolio of Ultra High Net Worth and Global Family Offices across a full suite of products with focus on FX Solutions in addition to the Global Family Office (GFIW) team & Financial Advisors in the Americas.

· Oversee corporate business with direct focus on revenue optimization balancing portfolio CVA, LRD, RWA and funding costs to increase economic profit. Reduced overall loan exposure globally since 2013 employing IB hurdle rate methodology and recalibrating client coverage while restructuring long-dated deals to achieve sustainable RoE on regulatory capital basis. · Actively cover multinational corporations with specific focus to technology, pharma, private equity and FIG sectors. Lead liaison to IBD involving strategic FX assignments creating event-driven hedge solutions for corporations and sponsors.· Developed framework for banking led strategic FX advisory (deal contingents, option structuring) while maintaining individual producer targets.

Head of US Corporate FX Sales· Managed North American Corporate FX Franchise integrating legacy Lehman team within existing FX platform. as well as a West Cost & Toronto coverage. · Expanded production across all sectors closing 2009 with high water mark in terms of new clients and production. Integrated Lehman investment banking platform to execute strategic FX derivatives. · Top-producing manager, exceeded targets and exceeded expectations by fostering a culture of excellence, resulting in exceptional team performance.· Achieved top NA Corporate FX desk ranking in Coalition Greenwich survey following team integration for 2009.

· Pioneered the conceptualization, development, and launch of Corporate FX Franchise starting with NY sales operations. Expanded corporate approach to European client base while coordinating marketing efforts globalizing the firm’s footprint.· Integrated strategic coverage through Investment Banking and Debt/Equity Capital Markets. Incorporated team within IBD Chinese Wall to source strategic FX assignments. Pioneered the use of deal contingent technology and managing deal concentration risk in cross-border M&A context in 2004.· Merged client coverage coordinating with IR Derivatives Team targeting >500 leads sourcing transactional FX and non-FX business via advisory-based approach. Customized corporate hedging programs. Led development of options, exotic options & eFX risk management and sales platforms.· Employed risk management policy framework and best-practices methodology which benchmarks hedging strategy and product usage across industry groups. Spearheaded the development and implementation of a comprehensive risk management framework with key technology clients that effectively benchmarked hedging strategies, resulting in increased efficiency and risk mitigation. Created and marketed proprietary Corporate FAS133 products and tax strategies.

· Developed strong core of corporate relationships (North America and Canada) through primary daily G10/EMG FX macro coverage and select M&A assignments. Account coverage specialty in technology, PE and pharmaceutical sectors.· Lead contact for NY structured FX products and execution. Structured hedging opportunities included Vanilla (Euro/Amer/Ber, Average Rate Options and Spreads) and Exotic (European/average rate basket option pricing, Enhanced Forwards, Single/Double/Windowed Barriers, Binaries/Digital/Range Payouts, Double Average Rates, Compounds, Notes). · Corporate advisory focused on: FX Value at Risk for Exposure Management and M&A Related FX Risks, Customization of Client Portfolios, Hedging Policy Analysis and Review, and Accounting Driven Client Structures/Solutions.

Various positions in FX Options, Spot and Emerging Markets Trading with the bulk of the period in Exotic FX Options trading and business development.· Created Global Exotics Trading, Sales & Operations business with Chief Exotic Options Trader managing pricing, execution and marketing of first and second generation exotic option products for both clients and interbank dealers. · Developed new products and building blocks with structuring group/DR serving as global liaison for strategy, distribution, legal and operations management. Constructed tailored exotic products for corporate, institutional and private clients.· Collaborated with cross-functional teams to in executing the strategic plan for market entry of Asian NDF market into NYC ensuring alignment with organizational goals. Enhanced Sales derivatives expertise and marketing by introducing new G10/EM non-deliverable option/swap pricing methodologies and strategies.

Consulted organizations to achieve operational excellence, cost savings, and improved overall performance through their expertise in analyzing and optimizing complex systems and processes.